A better future is in sight.
COMING SOON: AFFORDABLE OCT TO SCREEN EYE DISEASE
We’re ready to catch the quietest thief.
You could be going blind right now and have no idea. Most eye diseases quietly develop in your retina — without symptoms. That’s why routine screening is critical — to catch diseases early. Early enough to prevent eye diseases from stealing your vision. Another problem: the leading eye disease diagnostic technology, Optical Coherence Tomography (OCT), has been too expensive for most eyecare providers. Only the privileged few have had access to OCT systems worldwide.
IF DETECTED EARLY
What is OCT?
Optical Coherence Tomography is the light-equivalent to SONAR, sending signals to, then reflecting off of surfaces in order to measure depths of individual layers. Those collective signal measurements form an image of the retinal layers, where eye diseases quietly lurk, and can be accurately detected. Although OCT has been available for over 25 years, it remains an expensive technology to manufacture and operate. The use of high-quality optics, precision components and complex software have put this technology out of reach for most healthcare providers worldwide.
Affordable OCT is on its way.
Based on a breakthrough achieved by Dr. Adam Wax and his team at Duke University’s BIOS Lab, a patent-pending, low-cost, portable system has been devised that will revolutionize eye disease detection. Soon, more patients around the world will be able to have their retinas checked thanks to an affordable, portable OCT instrument. The Lumedica system is small, powerful and simple, it can be deployed as a stand-alone screening instrument, integrated with an Artificial-Intelligence data diagnostic, or as the front line of an eye care network.
Screening devices built by Lumedica Vision will go a long way toward reaching healthcare’s “triple aim.” For many providers, the Lumedica Vision device will be the very first OCT screening instrument they’ve been able to afford. They’ll love the price. They’ll love its portability. And the fact that they’ll finally be able to detect eye disease earlier than ever.
Int'l Opthamologists & Optometrists
High cost has prevented most of the world's eye professionals from using OCT.
U.S. Opthamologists & Optometrists
The low-cost and portability are attractive to providers treating underserved populations.
GP's will be able to screen retinas as part of a routine exam-- especially valuable for aging patients.
Original Equipment Manufacture (OEM)
The compact light engine complements other diagnostic technologies in integrated instruments.
Lumedica Vision is currently raising capital to fund development and regulatory clearance of its first clinical instrument. The round is currently open and will be closing no later than December, 2019. If you would like to participate in this round, please contact us.
Dr. Adam Wax – Interim CEO
- Professor of Biomedical Engineering in the Pratt School of Duke University
- Inventor of several technologies licensed to Lumedica
- Co-founder and board chairman at OncoScope. Raised $11M+ in capital
Dr. William Brown – CTO
- Co-founder of four companies in medical imaging and telecom
- Part of two successful exits
- Built commercially successful OCT product-line
Beth Hollister, RN – Director of Clinical Regulatory Affairs
- Founded, and sold Piedmont Research Labs
- Clinical Trials Manager Duke University Medical Center
- Clinical Trials Director for Harrier, Glycosan Pharmaceuticals
Michael Crose - Director of Product Development
- 15+ years optomechanical product design
- Developed R&D 100 and multiple SPIE Prism award winning products
- Migrated numerous designs from ideation to commercial products
Scott Whitney - Chief of Marketing
- 20+ years experience marketing and branding
- Served clients including HIMSS, Johnson & Johnson, IBM, Health Evolution Summit
- Experience in product development, sales strategy, web development, and UI design
Get in touch
404 HUNT STREET | SUITE 510
DURHAM, NORTH CAROLINA 27701